Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IMM-101 + ipilimumab
- Development stage
- Unknown
- Lead developer
- Immodulon Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intradermal, Intravenous
01
Overview
IMM-101 + ipilimumab is a combination immunotherapy regimen comprising **IMM-101**, a heat-killed whole cell *Mycobacterium obuense* preparation, and **ipilimumab**, a monoclonal antibody targeting CTLA-4. IMM-101 acts as a non-specific immune modulator that is believed to activate dendritic cells and enhance antigen presentation, stimulating a Th1/CTL cytokine response and potentially amplifying anti-tumor immunity. Ipilimumab is a checkpoint inhibitor that blocks cytotoxic T-lymphocyte associated protein 4 (CTLA-4) to increase T-cell activation against tumors. The combination is being investigated principally in **melanoma**, with evidence of synergistic anti-tumor responses and enhanced clinical outcomes over monotherapy in early clinical experiences.
- Other names
- IMM-101 + ipilimumabIMM-101/Ipilimumab
02
Targets
PRR (Pattern recognition receptors)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)
Beyond the preview
Go deeper on IMM-101 + ipilimumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IMM-101 + ipilimumab.